Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue
Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent ...
Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug
NEW YORK (Reuters) - Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene ...
Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...
manilatimes4d
Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
R&D Expenses: Research and development expenses for the third quarter of 2024 were $1.0 million, compared to $1.9 million for ...
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this ...
Treasury6d
Multipronged, Strategic Financial Risk Initiative Delivers Big Value for BMS
The winner of the 2024 Gold Alexander Hamilton Award in Financial Risk Management is Bristol Myers Squibb. Congratulations to ...